• Clarity receives $11.1 million R&D Tax Incentive refund
• Clarity is well funded with approximately $106 million in cash
• Clarity will prioritize development of 64/67Cu-SAR-bisPSMA, 64Cu-SARTATE, and 64Cu-SAR-Bombesin

Clarity Pharmaceuticals has received an $11.1 million R&D Tax Incentive refund, including interest, as part of the Australian Federal Government's R&D Tax Incentive program. This funding will provide additional resources to further the development of Clarity's Targeted Copper Theranostic (TCT) platform of products for various cancer indications. With the addition of the $11.1 million, Clarity is well funded with approximately $106 million in cash, the majority of which will be spent directly on research, development, and commercialization efforts. Following a review of its portfolio and market analysis, Clarity will prioritize the development of 64/67Cu-SAR-bisPSMA for both diagnostic and therapeutic applications in prostate cancer, 64Cu-SARTATE for neuroendocrine tumors (NETs) imaging, and 64Cu-SAR-Bombesin for prostate cancer imaging. As part of this prioritization process, the CL04 trial with 64/67Cu-SARTATE in pediatric high-risk neuroblastoma and the COMBAT trial with 64/67Cu-SAR-Bombesin in low prostate-specific membrane antigen (PSMA) metastatic castration-resistant prostate cancer (mCRPC) will be closed. Clarity will also continue to progress its Discovery Program, aiming to bring key assets such as 64Cu-SAR-bisFAP and 64/67Cu-SAR-trastuzumab to the clinic.

Clarity is well funded with approximately $106 million in cash, the majority of which will be spent directly on research, development, and commercialization endeavors in the company's key programs.

Clarity will prioritize the development of 64/67Cu-SAR-bisPSMA for both diagnostic and therapeutic applications in prostate cancer, 64Cu-SARTATE for NETs imaging, and 64Cu-SAR-Bombesin for prostate cancer imaging. The company will also continue to progress its Discovery Program, aiming to bring key assets to the clinic.